Daewon Pharmaceutical: "DW5524 Phase 2 Trial Plan Approved"
Pediatric syrup containing Pelubi's active ingredient
"A new treatment option for childhood fever"
Daewon Pharmaceutical said on Nov. 16 that the Ministry of Food and Drug Safety had approved the Phase 2 clinical trial plan for DW5524, a pediatric syrup containing pelubiprofen, the active ingredient in Pelubi Tab, Korea's 12th domestically developed novel drug.
DW5524 is a suspension syrup containing pelubiprofen in liquid form, developed with the medication-taking needs of pediatric patients in mind. Daewon Pharmaceutical is pursuing pediatric formulation development and clinical research to expand its existing fever treatment portfolio for adults to children.
The trial aims to enroll a total of 60 pediatric patients aged 2 to 12 with fever caused by acute upper respiratory tract infections. The primary endpoint is the reduction in body temperature four hours after administration. The trial will also assess the rate of temperature normalization, the time required for normalization, and adverse events.
The study is part of the Pediatric Disease Overcoming Research and Development Project, supported by the Ministry of Health and Welfare and the Korea Health Industry Development Institute. Daewon Pharmaceutical is leading the research, with Chungbuk National University Hospital and Gyeongsang National University Hospital participating. The goal is to complete the Phase 2 pediatric trial and obtain approval for a subsequent Phase 3 trial plan.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Daewon Pharmaceutical official said, "Building on our accumulated research experience, we will continue development to closely evaluate the antipyretic efficacy and safety in pediatric patients and provide a new treatment option for childhood fever."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.